GleamWall
中文EN

OGN Organon & Co.

Pharmaceutical Preparations · NYSE · SEC CIK 1821825 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-3.2%
TTM net income YoY-57.5%
TTM EPS YoY-59.2%
Revenue 3-yr CAGR-0.3%
Net income 3-yr CAGR-28.6%

Margins

Gross margin53.1%
Operating margin—
Net margin3.5%
FCF margin11.1%
EBITDA margin—

Returns

ROE20.3%
ROA1.6%
ROIC (approx.)—
Asset turnover0.45x

Leverage & solvency

Liabilities / assets91.1%
Debt / equity7.17x
Current ratio2.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income3.96x
Accruals ratio-4.7%
Payout ratio9.4%
Capex / revenue2.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.57B$1.56B$1.46B$1.51B$1.60B$1.59B$1.51B$1.59B
Cost of revenue$705.00M$711.00M$677.00M$766.00M$745.00M$720.00M$672.00M$696.00M
Gross profit$869.00M$847.00M$783.00M$741.00M$857.00M$874.00M$841.00M$896.00M
R&D expense$83.00M$90.00M$93.00M$91.00M$84.00M$95.00M$96.00M$130.00M
SG&A expense$421.00M$434.00M$424.00M$433.00M$415.00M$453.00M$420.00M$470.00M
Interest expense$106.00M$108.00M$111.00M$121.00M$128.00M$131.00M$124.00M$132.00M
Pretax income$255.00M$183.00M$213.00M-$148.00M$243.00M$229.00M$101.00M$129.00M
Income tax$91.00M$75.00M$67.00M$57.00M$83.00M$84.00M$14.00M$20.00M
Net income$164.00M$108.00M$146.00M-$205.00M$160.00M$145.00M$87.00M$109.00M
EPS (basic)0.620.410.56—0.610.560.34—
EPS (diluted)0.600.400.55—0.610.560.33—
Dividends declared per share0.020.020.020.020.020.020.280.28
Weighted avg. shares (diluted)272.38M270.45M262.90M—260.65M260.16M261.00M—
Balance sheet
Cash & equivalents$1.46B$1.13B$1.12B$574.00M$672.00M$599.00M$547.00M$675.00M
Receivables$1.48B$1.49B$1.38B$1.33B$1.48B$1.48B$1.46B$1.36B
Inventory$1.35B$1.35B$1.37B$1.41B$1.49B$1.45B$1.36B$1.32B
Current assets$5.37B$5.11B$4.93B$4.35B$4.70B$4.62B$4.37B$4.35B
PP&E, net$1.29B$1.28B$1.28B$1.30B$1.29B$1.27B$1.20B$1.17B
Goodwill$4.15B$4.15B$4.15B$4.15B$4.68B$4.68B$4.68B$4.68B
Intangibles$1.06B$1.11B$1.10B$1.13B$1.34B$1.36B$1.42B$1.41B
Total assets$13.40B$13.18B$13.00B$12.87B$13.55B$13.50B$13.16B$13.10B
Current liabilities$2.65B$2.62B$2.50B$2.39B$2.68B$2.80B$2.62B$2.72B
Short-term debt$69.00M$74.00M$16.00M$16.00M$45.00M$115.00M$20.00M$20.00M
Long-term debt$8.48B$8.48B$8.55B$8.63B$8.78B$8.78B$8.94B$8.86B
Total debt$8.55B$8.55B$8.57B$8.64B$8.83B$8.90B$8.96B$8.88B
Total liabilities$12.21B$12.17B$12.09B$12.12B$12.65B$12.77B$12.61B$12.63B
Shareholders' equity$1.19B$1.01B$903.00M$752.00M$906.00M$733.00M$542.00M$472.00M
Net debt$7.10B$7.42B$7.45B$8.07B$8.16B$8.30B$8.41B$8.21B
Shares outstanding262.62M262.61M262.65M260.32M259.98M259.96M257.95M257.80M
Cash flow statement
Operating cash flow$370.00M$107.00M$225.00M$141.00M$264.00M$220.00M$75.00M$390.00M
Capital expenditure$44.00M$42.00M$37.00M$45.00M$46.00M$39.00M$32.00M$55.00M
Free cash flow$326.00M$65.00M$188.00M$96.00M$218.00M$181.00M$43.00M$335.00M
Investing cash flow-$44.00M-$76.00M$386.00M-$65.00M-$115.00M-$38.00M-$172.00M-$296.00M
Financing cash flow-$5.00M-$12.00M-$38.00M-$187.00M-$76.00M-$223.00M-$75.00M-$82.00M
Depreciation & amortization$34.00M$34.00M$39.00M$46.00M$40.00M$36.00M$34.00M$34.00M
Stock-based compensation$21.00M$25.00M$19.00M$7.00M$24.00M$22.00M$24.00M$26.00M
Dividends paid$5.00M$6.00M$5.00M$4.00M$3.00M$10.00M$71.00M$74.00M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.